左心室辅助装置支持下的腹膜透析患者。

IF 2.2 3区 医学 Q3 ENGINEERING, BIOMEDICAL
Zurab Darbaidze, Bastian Schmack, Günes Dogan, Ali Saad Merzah, Maria M Gabriel, Adelheid Görler, Aron-Frederik Popov, Alexander Weymann, Arjang Ruhparwar, Jan D Schmitto, Jasmin S Hanke
{"title":"左心室辅助装置支持下的腹膜透析患者。","authors":"Zurab Darbaidze, Bastian Schmack, Günes Dogan, Ali Saad Merzah, Maria M Gabriel, Adelheid Görler, Aron-Frederik Popov, Alexander Weymann, Arjang Ruhparwar, Jan D Schmitto, Jasmin S Hanke","doi":"10.1111/aor.14970","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Terminal heart failure is often associated with end-stage kidney disease. Due to advantages concerning patient independence, peritoneal dialysis (PD) is an alternative to conventional hemodialysis treatment. As left ventricular assist device implantations continuously increase, data on combined PD and LVAD is rare. We present the first and largest cohort study on this exclusive patient cohort.</p><p><strong>Methods: </strong>A retrospective study was conducted on patients who underwent LVAD implantation at a high-volume heart failure center from 2000 to 2024. Adverse events were analyzed according to the INTERMACS classification.</p><p><strong>Results: </strong>A total of nine patients were identified as undergoing PD on LVAD therapy. Mean age at the time of LVAD implantation was 67 years. Main cause of kidney disease was cardio-renal syndrome (67%). In all patients, PD therapy was established before LVAD implantation. Mean time on PD before LVAD implantation was 72 months. None of the patients were weaned from dialysis nor were converted to conventional dialysis. Four patients experienced driveline infection. Three patients suffered an infection of their PD catheter. A combination of PD and DL infection was detected in two cases. None of these infections were associated with the same pathogens. Mean survival after LVAD + PD was 56.5 months.</p><p><strong>Conclusion: </strong>Peritoneal dialysis has advantages over hemodialysis including fewer bloodstream infections, fewer hemodynamic shifts, and the comfort of the ambulant setting. This study illustrates that PD in LVAD patients is feasible and long-term support up to several years is achievable without major complications.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Peritoneal Dialysis in Patients Supported by Left Ventricular Assist Device.\",\"authors\":\"Zurab Darbaidze, Bastian Schmack, Günes Dogan, Ali Saad Merzah, Maria M Gabriel, Adelheid Görler, Aron-Frederik Popov, Alexander Weymann, Arjang Ruhparwar, Jan D Schmitto, Jasmin S Hanke\",\"doi\":\"10.1111/aor.14970\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Terminal heart failure is often associated with end-stage kidney disease. Due to advantages concerning patient independence, peritoneal dialysis (PD) is an alternative to conventional hemodialysis treatment. As left ventricular assist device implantations continuously increase, data on combined PD and LVAD is rare. We present the first and largest cohort study on this exclusive patient cohort.</p><p><strong>Methods: </strong>A retrospective study was conducted on patients who underwent LVAD implantation at a high-volume heart failure center from 2000 to 2024. Adverse events were analyzed according to the INTERMACS classification.</p><p><strong>Results: </strong>A total of nine patients were identified as undergoing PD on LVAD therapy. Mean age at the time of LVAD implantation was 67 years. Main cause of kidney disease was cardio-renal syndrome (67%). In all patients, PD therapy was established before LVAD implantation. Mean time on PD before LVAD implantation was 72 months. None of the patients were weaned from dialysis nor were converted to conventional dialysis. Four patients experienced driveline infection. Three patients suffered an infection of their PD catheter. A combination of PD and DL infection was detected in two cases. None of these infections were associated with the same pathogens. Mean survival after LVAD + PD was 56.5 months.</p><p><strong>Conclusion: </strong>Peritoneal dialysis has advantages over hemodialysis including fewer bloodstream infections, fewer hemodynamic shifts, and the comfort of the ambulant setting. This study illustrates that PD in LVAD patients is feasible and long-term support up to several years is achievable without major complications.</p>\",\"PeriodicalId\":8450,\"journal\":{\"name\":\"Artificial organs\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-02-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Artificial organs\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1111/aor.14970\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENGINEERING, BIOMEDICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Artificial organs","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1111/aor.14970","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

摘要

终末期心力衰竭常与终末期肾脏疾病相关。由于在患者独立性方面的优势,腹膜透析(PD)是传统血液透析治疗的替代方案。随着左室辅助装置的植入不断增加,PD和LVAD合并的数据很少。我们提出了第一个也是最大的针对这一患者队列的队列研究。方法:回顾性分析2000 - 2024年在某大容量心力衰竭中心行LVAD植入术的患者。根据INTERMACS分类对不良事件进行分析。结果:共有9例患者在LVAD治疗下接受PD治疗。LVAD植入时的平均年龄为67岁。肾脏疾病的主要原因是心肾综合征(67%)。在所有患者中,PD治疗都是在LVAD植入前建立的。LVAD植入前PD的平均时间为72个月。所有患者均未脱离透析,也未转为常规透析。4例患者出现了传动系统感染。3例患者PD导管感染。2例合并PD和DL感染。这些感染都与相同的病原体无关。LVAD + PD后的平均生存期为56.5个月。结论:腹膜透析优于血液透析,包括更少的血流感染、更少的血流动力学变化和更舒适的走动环境。本研究表明,LVAD患者PD是可行的,并且可以实现长达数年的长期支持,且无重大并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Peritoneal Dialysis in Patients Supported by Left Ventricular Assist Device.

Introduction: Terminal heart failure is often associated with end-stage kidney disease. Due to advantages concerning patient independence, peritoneal dialysis (PD) is an alternative to conventional hemodialysis treatment. As left ventricular assist device implantations continuously increase, data on combined PD and LVAD is rare. We present the first and largest cohort study on this exclusive patient cohort.

Methods: A retrospective study was conducted on patients who underwent LVAD implantation at a high-volume heart failure center from 2000 to 2024. Adverse events were analyzed according to the INTERMACS classification.

Results: A total of nine patients were identified as undergoing PD on LVAD therapy. Mean age at the time of LVAD implantation was 67 years. Main cause of kidney disease was cardio-renal syndrome (67%). In all patients, PD therapy was established before LVAD implantation. Mean time on PD before LVAD implantation was 72 months. None of the patients were weaned from dialysis nor were converted to conventional dialysis. Four patients experienced driveline infection. Three patients suffered an infection of their PD catheter. A combination of PD and DL infection was detected in two cases. None of these infections were associated with the same pathogens. Mean survival after LVAD + PD was 56.5 months.

Conclusion: Peritoneal dialysis has advantages over hemodialysis including fewer bloodstream infections, fewer hemodynamic shifts, and the comfort of the ambulant setting. This study illustrates that PD in LVAD patients is feasible and long-term support up to several years is achievable without major complications.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Artificial organs
Artificial organs 工程技术-工程:生物医学
CiteScore
4.30
自引率
12.50%
发文量
303
审稿时长
4-8 weeks
期刊介绍: Artificial Organs is the official peer reviewed journal of The International Federation for Artificial Organs (Members of the Federation are: The American Society for Artificial Internal Organs, The European Society for Artificial Organs, and The Japanese Society for Artificial Organs), The International Faculty for Artificial Organs, the International Society for Rotary Blood Pumps, The International Society for Pediatric Mechanical Cardiopulmonary Support, and the Vienna International Workshop on Functional Electrical Stimulation. Artificial Organs publishes original research articles dealing with developments in artificial organs applications and treatment modalities and their clinical applications worldwide. Membership in the Societies listed above is not a prerequisite for publication. Articles are published without charge to the author except for color figures and excess page charges as noted.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信